Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cytomegalovirus GB antigen

A cytomegalovirus and cell technology, applied in the field of immune response compositions, can solve the problems of abnormal development of the central nervous system, poor mental performance and the like

Active Publication Date: 2013-08-07
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF23 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, follow-up studies have shown that 15% of these infants will have sequelae, such as hearing loss or abnormal development of the central nervous system, resulting in poorer mental performance, among other things

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cytomegalovirus GB antigen
  • Cytomegalovirus GB antigen
  • Cytomegalovirus GB antigen

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0133] a) a cytomegalovirus (CMV) gB polypeptide, in the N-terminal to C-terminal direction, comprising: an extracellular domain comprising at least a portion of a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, either Optionally at least a portion of the transmembrane (TM) domain, and at least a portion of the cytoplasmic domain, wherein at least one amino acid of the FL1 domain is substituted or deleted, and wherein the TM domain or portion thereof, if present, is non-functional.

[0134] b) The CMV gB polypeptide of embodiment a), wherein the TM domain is rendered non-functional by deletion of amino acids at positions 701-775 relative to the sequence shown in SEQ ID NO: 1 or at corresponding positions in other CMV gB polypeptides .

[0135] c) The CMV gB polypeptide of embodiment a) or b), further comprising at least one amino acid substitution or deletion in the FL2 domain of the fusion loop.

[0136] d) The CMV gB polypeptide of any one of embodiments a) to ...

Embodiment 1

[0169] Embodiment 1: CMV gB polypeptide

[0170] All gB polypeptide variants specified below (for illustration see figure 1 and figure 2 ) is derived from the amino acid sequence of gB of CMV strain AD169. Accordingly, when specifying mutation positions, the numbering of amino acids is relative to the sequence of AD169 CMV gB set forth in SEQ ID NO:1. In addition, the following constructs (i) all deleted the transmembrane domain (deleted amino acids 701 to 775) and (ii) all contained the following point mutations: replacing amino acid R with amino acid S, in addition to the specific mutations they each contain as described below 50 and R 357 .

[0171] Although the following variants contain a histidine tag at the C-terminus of the polypeptide used for transient transfection, the sequence of the tag is not included in the SEQ ID disclosed therein.

[0172] 1.1 gB-SLP12

[0173] The gB-SLP12 variant contains 2 series of point mutations targeting the putative fusion lo...

Embodiment 2

[0209] Example 2: Expression of CMV gB polypeptides

[0210] Using FreeStyle from Invitrogen TM MAX CHO Expression System The various DNA constructs described above were transiently transfected into CHO (Chinese Hamster Ovary) cells. A construct encoding the polypeptide gB-Delta™ was used as a control. The amino acid sequence of gB-Delta™ is given as SEQ ID NO:2. The expression vector used to express gB-DeltaTM was pMax-AD169. FreeStyle TM MAX CHO uses the CHO-S cell line (the common CHO-K1 cell line is adapted to a separate subclone in suspension) and a synthetic cationic lipid based polymer as a transfection reagent. Plasmid DNA for transfection was isolated using the Qiagen Maxiprep kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Transfection complexes were prepared as recommended by Invitrogen. Briefly, 37.5 μg plasmid and 37.5 μl FreeStyle MAX transfection reagent were diluted in 0.6 ml Opti-Pro TM in SFM medium. Immediately thereafter, add ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a cytomegalovirus (CMV) gB polypeptide comprising at least a portion of a gB protein extracellular domain comprising a fusion loop 1 (FL1) domain and a fusion loop 2 (FL2) domain, wherein at least one of the FL1 and FL2 domains comprises at least one amino acid deletion or substitution.

Description

technical field [0001] The present invention relates to the field of immunology. In particular, the present invention provides compositions, such as, for example, vaccines, and methods for eliciting an immune response specific for cytomegalovirus (CMV). technical background [0002] Human cytomegalovirus (HCMV) is a ubiquitous DNA virus belonging to the herpesvirus family. HCMV consists of a DNA core, an outer capsid, and is covered by a lipid membrane containing virus-specific glycoproteins. [0003] HCMV is endemic in most parts of the world. However, primary infection usually results in subclinical disease, after which the virus becomes latent, retaining the ability to reactivate at any later time. However, in both groups, HCMV caused serious medical conditions. HCMV is the leading cause of birth defects in neonates infected in utero. This is the most common cause of congenital infection in developed countries. Congenital infections are infections that are passed fr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/245C07K14/045
CPCC12N2710/16122A61K39/245C07K14/03C12N2710/16134C07K14/005A61K2039/55555A61K2039/55572A61K2039/55577A61K39/12A61P31/22C07K14/045
Inventor G.J.M.F.P.鲍道克斯N.布莱斯M.马汉德
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com